Treatment of unresectable malignant pleural mesothelioma in 2021: emerging standards in immunotherapy - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Treatment of unresectable malignant pleural mesothelioma in 2021: emerging standards in immunotherapy write by Bailey G. Fitzgerald. This book was released on 2021-08-05. Treatment of unresectable malignant pleural mesothelioma in 2021: emerging standards in immunotherapy available in PDF, EPUB and Kindle. Patients with unresectable malignant pleural mesothelioma (MPM) have historically poor outcomes and treatment, and their treatments have been limited to palliative chemotherapy. Recent efforts to improve prognosis for these patients by adding angiogenesis inhibitors to chemotherapy led to significant benefits. However, the emergence of immunotherapy combinations for the front-line treatment has upended the standard of care and has led to the first new FDA approvals for the treatment of MPM in nearly two decades. This review aims to cover the main clinical trials in unresectable MPM with VEGF inhibitors and immunotherapy which have led to paradigm shifts in current practice. Ongoing clinical trials exploring the combination of chemo and immunotherapies show a great deal of promise, and continued support for ambitious, large-scale well-designed trials remain vital for defining the future outcomes of patients diagnosed with MPM.
Emerging Therapies for Malignant Mesothelioma
Emerging Therapies for Malignant Mesothelioma - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Emerging Therapies for Malignant Mesothelioma write by Nico van Zandwijk. This book was released on 2020-07-17. Emerging Therapies for Malignant Mesothelioma available in PDF, EPUB and Kindle.
100 Questions & Answers About Mesothelioma
100 Questions & Answers About Mesothelioma - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook 100 Questions & Answers About Mesothelioma write by Harvey I. Pass. This book was released on 2009-06-11. 100 Questions & Answers About Mesothelioma available in PDF, EPUB and Kindle. Whether you're a newly diagnosed Mesothelioma patient, a survivor, or a friend or relative of either, this book offers help. The only book to provide the doctor's and patient's views, 100 Questions & Answers About Mesothelioma, Third Edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, legal options, and much more. This outstanding team of authors -- led by a world-class lung disease expert -- provides an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease.
Focus on Malignant Pleural Mesothelioma Immunology and Immunotherapy
Focus on Malignant Pleural Mesothelioma Immunology and Immunotherapy - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Focus on Malignant Pleural Mesothelioma Immunology and Immunotherapy write by Christophe Blanquart. This book was released on 2023-08-15. Focus on Malignant Pleural Mesothelioma Immunology and Immunotherapy available in PDF, EPUB and Kindle. Malignant pleural mesothelioma (MPM) is a rare thoracic cancer that derives from the mesothelial cells of the pleura and is causally associated with exposure to asbestos. Because of its aggressiveness and resistance to therapies, MPM prognosis is extremely poor and the 5-year survival rate is approximately 10%. Despite its poor effectiveness, chemotherapy with cisplatin and pemetrexed has long remained the standard-of-care for upfront treatment with no second line therapy available. Recently, the approval of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) for the first-line treatment of unresectable MPM has marked a significant milestone, in particular for the non-epithelioid MPM subtype, which is more resistant to chemotherapy and associated with a poorer outcome. However, most MPM patients are still resistant to cancer therapies. Beyond histologic subtypes, recent studies have highlighted extensive genetic variation and gene expression deregulation both between and within MPM patients. This molecular heterogeneity highlights the need for a personalized treatment approach. Therefore, both multiple therapeutic options and predictive biomarkers that can guide clinical decision-making are urgently needed. Tumor cell immunogenicity and tumor microenvironment composition (TME) are the major determinants of the success of immunotherapy. Despite the low tumor mutational burden, recent studies indicate that chromoanagenesis and chromotripsis are molecular features of MPM. Since chromosomal instability can lead to the expression of neo-antigens, it could also influence the efficacy of immune checkpoint inhibitors (ICIs). The immunosuppressive TME is an additional important hurdle that limits the efficacy of immunotherapy. The combination of ICIs with strategies to boost anti-tumor immunity by restraining immunosuppressive myeloid cells or by reprograming “cold tumor” into “hot tumor” is an active area of research. This Research Topic aims to discuss recent advances in understanding and targeting MPM immune microenvironment for therapeutic purposes along with potential predictive biomarkers to select patients who most likely will respond to immunotherapies. We are interested in basic and clinical studies that explore the crosstalk between tumor and immune cells in order to highlight new molecular targets, approaches, and combination treatments to enhance anti-tumor immunity in MPM and assess potential predictive biomarkers of response to immunotherapy.
Immunotherapy in Malignant Pleural Mesothelioma
Immunotherapy in Malignant Pleural Mesothelioma - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Immunotherapy in Malignant Pleural Mesothelioma write by Nobukazu Fujimoto. This book was released on 2020. Immunotherapy in Malignant Pleural Mesothelioma available in PDF, EPUB and Kindle. Malignant pleural mesothelioma (MPM) is an extremely aggressive plural malignancy mainly caused by asbestos exposure. Basic research about the immune suppressive tumor microenvironment in MPM has suggested that MPM might be a good candidate for immune therapy. Immunocheckpoint inhibitors have shown some promising results. A phase Ib trial with pembrolizumab, an antibody specific for the programmed cell death 1 protein (anti-PD-1), showed efficacy in patients with programmed death-ligand 1 (PD-L1)-positive MPM. Among 25 patients tested, 5 patients (20%) achieved a partial response. A Japanese group evaluated the efficacy and safety of nivolumab, an anti-PD-L1 antibody, for patients with advanced MPM in a phase II study. Ten (29%) patients showed an objective response. Based on those results, nivolumab was approved in Japan for unresectable recurrent MPM. A phase III randomized study was conducted to compare nivolumab plus ipilimumab to platinum doublet chemotherapy as a first-line therapy in unresectable MPM. The primary endpoint, overall survival (OS), was significantly improved in the nivolumab plus ipilimumab group. Cellular therapies and cancer vaccines are limited by many challenges; therefore, improvements to overcome these difficulties are urgently warranted. Further research is needed, including large-scale clinical trials, to clarify the utility and safety of immunotherapy in MPM.
